MT Group Surpasses 5,000 Customized Biospecimen Collections, Reinforcing Its Position as a Leading Specialty CRO for Prospective Human Tissue and Blood Procurement
23-year-old biospecimen CRO marks milestone with expanded capabilities for translational research, biomarker discovery, companion diagnostic development, and liquid biopsy validation across oncology and autoimmune programs LOS ANGELES, June 2, 2026 /PRNewswire/ -- MT Group, a specialty...
23-year-old biospecimen CRO marks milestone with expanded capabilities for translational research, biomarker discovery, companion diagnostic development, and liquid biopsy validation across oncology and autoimmune programs LOS ANGELES, June 2, 2026 /PRNewswire/ -- MT Group, a specialty...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.